Status:
COMPLETED
Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborating Sponsors:
Patient-Centered Outcomes Research Institute
Conditions:
Chronic Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Investigators will compare Clinical Decision Support (CDS) versus Patient Education and Activation Tools (PEATs) in patients prescribed long-term or multiple opioids to measure outcomes that are impor...
Detailed Description
Investigators will compare two strategies: (1) Engage PCPs with Clinical Decision Support at the point of care, raising active alerts through the Electronic Health Record (EHR) when there is risk of i...
Eligibility Criteria
Inclusion
- Within a 90-day period prior to the patient recruitment date:
- ≥30 days of prescriptions for opioid medications; or
- 2 or more opioid prescriptions; or
- a total amount of ≥700 Morphine Milligram Equivalents (MME) in a single opioid prescription;
- and
- Patients who have had 1 or more Cedars-Sinai Medical Group primary care physician in the year prior to the study start date; and
- At least 1 visit during the follow-up year (the follow-up year will start after they consent to be in the study).
- Prescriptions in the inpatient setting will not make a patient eligible for this study.
Exclusion
- Individuals less than 18 years of age; or
- Individuals with any cancer treatment (chemotherapy or radiotherapy) administered 180 days or less prior to patient recruitment; or
- Individuals with a cancer diagnosis in the Problem List 180 days or less prior to patient recruitment (patients with cancer surveillance only will be included in the study); or
- Individuals with palliative care treatment administered 180 days or less prior to patient recruitment; or
- Individuals with any end-of-life treatment (comfort care) prior to patient recruitment; or
- Patients currently taking prescription medications (e.g. Suboxone, subutex, Buprenex, Butrans, Probuphine, Belbuca, buprenorphine/naloxone, Zubsolv, and Bunavail) for Opioid Use or other Substance Use Disorder treatment.
Key Trial Info
Start Date :
November 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
983 Patients enrolled
Trial Details
Trial ID
NCT03301623
Start Date
November 13 2017
End Date
December 31 2019
Last Update
October 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048